Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is notifying investors that class action lawsuits have been filed against Inogen, Inc. (“Inogen” or the “Company”) (NASDAQ:INGN), and certain other defendants, related to alleged violations of federal securities laws. If you purchased Inogen common stock between November 8, 2017 and February 26, 2019, you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information.

Inogen is a medical technology company specializing in the design and manufacture of portable oxygen concentrators.

The complaints allege that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) Inogen overstated the true size of the total addressable market (“TAM”) for its portable oxygen concentrators and misstated the basis for its calculation of the TAM; (ii) Inogen falsely attributed its sales growth to the strong sales acumen of its salesforce, when it was actually due in large part to sales tactics designed to deceive its elderly customer base; (iii) the growth in Inogen’s domestic business-to-business sales to home medical equipment (“HME”) providers was inflated, unsustainable, and eroding direct-to-consumer sales; and (iv) very little of Inogen’s business was actually coming from the more stable Medicare market.

On November 6, 2018, Inogen announced third quarter 2018 financial results, revealing that growth in its domestic business-to-business sales to HME providers had slowed and reducing guidance for fiscal 2018 adjusted EBITDA.

As a result of this news, the price of Inogen stock fell $37.44 per share – over 19% – to close at $155.86 per share.

Then, on February 26, 2019, after the close of trading, Inogen announced disappointing fourth quarter and fiscal year 2018 financial results and significantly reduced its previously provided fiscal 2019 net income guidance. Inogen’s CEO also backtracked on the Company’s prior TAM estimate and blamed Inogen’s poor domestic business-to-business sales on order activity that slowed from one national homecare provider.

On this news, the price of Inogen stock fell an additional $33.78 per share – over 24% – from a close of $140.06 per share on February 26, 2019, to a close of $106.28 per share on February 27, 2019.

What You Can Do

If you purchased Inogen stock between November 8, 2017 and February 26, 2019, inclusive, or if you have questions about this notice or your legal rights, please contact attorney Joe Pettigrew at (844) 818-6982 or jpettigrew@scott-scott.com. The lead plaintiff deadline is May 6, 2019.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising